Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


VeriFlex stent

This article was originally published in The Gray Sheet

Executive Summary

An item in FDA's Feb. 17 public listing of device recalls drew attention to Boston Scientific's recent move to rename its Taxus Liberté bare-metal coronary stent VeriFlex Bare-Metal. After hearing from cardiac cath labs that health care providers were inadvertently selecting Liberté bare-metal stents when the interventional cardiologist intended to implant a Liberté drug-eluting stent and vice-versa, the firm decided to rename the bare-metal version. In the recall, initiated last September, company reps visited all affected health care facilities and re-labeled the outer boxes of Liberté bare-metal stents to reflect the new name. The same month, FDA approved Boston Scientific's PMA supplement seeking to use the new trade name (1"The Gray Sheet" Nov. 2, 2009). Liberté paclitaxel-eluting stents continue to go by their original name

You may also be interested in...

Chart: FDA's September 2009 Report of Medical Device Approvals

FDA's September 2009 Report of Medical Device Approvals

Rx List Price Inflation Penalty Endorsed By US HHS Secretary

Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.

Generics Approvals Will Decline, US FDA Predicts, But Supplement Work May Grow

With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts